{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T23:17:23Z","timestamp":1790551043035,"version":"4.1.0"},"reference-count":36,"publisher":"American Association for Cancer Research (AACR)","issue":"3","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tuberous sclerosis complex is caused by mutations in tumor suppressor genes TSC1 or TSC2 and is characterized by the presence of hamartomas in many organs. Although tuberous sclerosis complex is a tumor suppressor gene syndrome with classic \u201csecond hits\u201d detectable in renal tumors, conventional genetic analysis has not revealed somatic inactivation of the second allele in the majority of human brain lesions. We demonstrate a novel mechanism of post-translational inactivation of the TSC2 protein, tuberin, by physiologically inappropriate phosphorylation, which is specific to tuberous sclerosis complex-associated brain lesions. Additional analysis shows that tissue specificity is due to abnormal activation of the Akt and mitogen-activated protein kinase pathways in brain but not in renal tumors. These results have widespread implications for understanding the tissue specificity of tumor suppressor gene phenotypes.<\/jats:p>","DOI":"10.1158\/0008-5472.can-03-3277","type":"journal-article","created":{"date-parts":[[2005,9,20]],"date-time":"2005-09-20T22:37:13Z","timestamp":1127255833000},"page":"812-816","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Phosphorylation of Tuberin as a Novel Mechanism for Somatic Inactivation of the Tuberous Sclerosis Complex Proteins in Brain Lesions"],"prefix":"10.1158","volume":"64","author":[{"given":"Sangyeul","family":"Han","sequence":"first","affiliation":[{"name":"1Molecular Neurogenetics Unit,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu\u0301lio M.","family":"Santos","sequence":"additional","affiliation":[{"name":"1Molecular Neurogenetics Unit,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Puga","sequence":"additional","affiliation":[{"name":"1Molecular Neurogenetics Unit,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenn","family":"Roy","sequence":"additional","affiliation":[{"name":"2Molecular Neuro-Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Thiele","sequence":"additional","affiliation":[{"name":"3Department of Neurology, Harvard Medical School\/Massachusetts General Hospital, Charlestown, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"McCollin","sequence":"additional","affiliation":[{"name":"3Department of Neurology, Harvard Medical School\/Massachusetts General Hospital, Charlestown, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Stemmer-Rachamimov","sequence":"additional","affiliation":[{"name":"2Molecular Neuro-Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijaya","family":"Ramesh","sequence":"additional","affiliation":[{"name":"1Molecular Neurogenetics Unit,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2004,2,10]]},"reference":[{"key":"2022061620195957600_B1","doi-asserted-by":"crossref","unstructured":"Gomez M. Definition and Criteria for Diagnosis Gomez M. Sampson J. Holtes-Whittemore V. eds. . Tuberous Sclerosis Complex, Ed. 3 11-23, Oxford University Press New York \u20081999.","DOI":"10.1093\/oso\/9780195122107.003.0002"},{"key":"2022061620195957600_B2","doi-asserted-by":"crossref","unstructured":"Identification and characterization of the tuberous sclerosis gene on chromosome 16. The European Chromosome 16 Tuberous Sclerosis Consortium. Cell, 75:\u20081305-1315, \u20081993.","DOI":"10.1016\/0092-8674(93)90618-Z"},{"key":"2022061620195957600_B3","doi-asserted-by":"crossref","unstructured":"van Slegtenhorst M., deHoogst R., Hermans C., Nellist M., Janssen B., Verhoef S., Lindhout D., et al Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science (Wash. DC), 277:\u2008805-808, \u20081997.","DOI":"10.1126\/science.277.5327.805"},{"key":"2022061620195957600_B4","doi-asserted-by":"crossref","unstructured":"Goncharova E. A., Goncharov D. A., Eszterhas A., Hunter D. S., Glassberg M. K., Yeung R. S., Walker C. L., Noonan D., Kwiatkowski D. J., Chou M. M., et al Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation: a role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J. Biol. Chem., 277:\u200830958-30967, \u20082002.","DOI":"10.1074\/jbc.M202678200"},{"key":"2022061620195957600_B5","doi-asserted-by":"crossref","unstructured":"Jaeschke A., Hartkamp J., Saitoh M., Roworth W., Nobukuni T., Hodges A., Sampson J., Thomas G., Lamb R. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent. J. Cell Biol., 159:\u2008217-224, \u20082002.","DOI":"10.1083\/jcb.jcb.200206108"},{"key":"2022061620195957600_B6","unstructured":"Kenerson H. L., Aicher L. D., True L. D., Yeung R. S. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res., 62:\u20085645-5650, \u20082002."},{"key":"2022061620195957600_B7","doi-asserted-by":"crossref","unstructured":"Kwiatkowski D. J., Zhang H., Bandura J. L., Heiberger K. M., Glogauer M., el-Hashemite N., Onda H. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum. Mol. Genet., 11:\u2008525-534, \u20082002.","DOI":"10.1093\/hmg\/11.5.525"},{"key":"2022061620195957600_B8","doi-asserted-by":"crossref","unstructured":"Gao X., Zhang Y., Arrazola P., Hino O., Kobayashi T., Yeung R. S., Ru B., Pan D. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat. Cell Biol., 4:\u2008699-704, \u20082002.","DOI":"10.1038\/ncb847"},{"key":"2022061620195957600_B9","doi-asserted-by":"crossref","unstructured":"Inoki K., Li Y., Zhu T., Wu J., Guan K. L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol., 4:\u2008648-657, \u20082002.","DOI":"10.1038\/ncb839"},{"key":"2022061620195957600_B10","doi-asserted-by":"crossref","unstructured":"Tee A. R., Fingar D. C., Manning B. D., Kwiatkowski D. J., Cantley L. C., Blenis J. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc. Natl. Acad. Sci. USA, 99:\u200813571-13576, \u20082002.","DOI":"10.1073\/pnas.202476899"},{"key":"2022061620195957600_B11","doi-asserted-by":"crossref","unstructured":"Manning B. D., Tee A. R., Logsdon M. N., Blenis J., Cantley L. C. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase\/akt pathway. Mol. Cell., 10:\u2008151-162, \u20082002.","DOI":"10.1016\/S1097-2765(02)00568-3"},{"key":"2022061620195957600_B12","doi-asserted-by":"crossref","unstructured":"Dan H. C., Sun M., Yang L., Feldman R. I., Sui X. M., Ou C. C., Nellist M., Yeung R. S., Halley D. J., Nicosia S. V., et al Phosphatidylinositol 3-kinase\/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J. Biol. Chem., 277:\u200835364-35370, \u20082002.","DOI":"10.1074\/jbc.M205838200"},{"key":"2022061620195957600_B13","doi-asserted-by":"crossref","unstructured":"Potter C. J., Pedraza L. G., Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell Biol., 4:\u2008658-665, \u20082002.","DOI":"10.1038\/ncb840"},{"key":"2022061620195957600_B14","doi-asserted-by":"crossref","unstructured":"Plas D. R., Thompson C. B. Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. J. Biol. Chem., 278:\u200812361-12366, \u20082003.","DOI":"10.1074\/jbc.M213069200"},{"key":"2022061620195957600_B15","doi-asserted-by":"crossref","unstructured":"Garami A., Zwartkruis F., Nobukuni T., Joaquin M., Roccio M., Stocker H., Kozma S., Hafen E., Bos J., Thomas G. Insulin activation of Rheb, a mediator of mTOR\/S6K\/4E-BP signaling is inhibited by TSC1 and 2. Mol. Cell, 11:\u20081457-1466, \u20082003.","DOI":"10.1016\/S1097-2765(03)00220-X"},{"key":"2022061620195957600_B16","doi-asserted-by":"crossref","unstructured":"Stocker H., Radimerski T., Schindelholz B., Wittwer F., Belawat P., Daram P., Breuer S., Thomas G., Hafen E. Rheb is an essential regulator of S6K in controlling cell growth in Drosophila. Nat. Cell Biol., 5:\u2008559-565, \u20082003.","DOI":"10.1038\/ncb995"},{"key":"2022061620195957600_B17","doi-asserted-by":"crossref","unstructured":"Zhang Y., Gao X., Saucedo L. J., Ru B., Edgar B. A., Pan D. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat. Cell Biol., 5:\u2008578-581, \u20082003.","DOI":"10.1038\/ncb999"},{"key":"2022061620195957600_B18","unstructured":"Henske E. P., Scheithauer B. W., Short M. P., Wollmann R., Nahmias J., Hornigold N., van Slegtenhorst M., Welsh C. T., Kwiatkowski D. J. Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am. J. Hum. Genet., 59:\u2008400-406, \u20081996."},{"key":"2022061620195957600_B19","doi-asserted-by":"crossref","unstructured":"Niida Y., Stemmer-Rachamimov A. O., Logrip M., Tapon D., Perez R., Kwiatkowski D. J., Sims K., MacCollin M., Louis D. N., Ramesh V. Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions. Am. J. Hum. Genet., 69:\u2008493-503, \u20082001.","DOI":"10.1086\/321972"},{"key":"2022061620195957600_B20","doi-asserted-by":"crossref","unstructured":"El-Hashemite N., Zhang H., Henske E. P., Kwiatkowski D. J. Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet, 361:\u20081348-1349, \u20082003.","DOI":"10.1016\/S0140-6736(03)13044-9"},{"key":"2022061620195957600_B21","doi-asserted-by":"crossref","unstructured":"Roach E. S., Gomez M. R., Northrup H. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J. Child Neurol., 13:\u2008624-628, \u20081998.","DOI":"10.1177\/088307389801301206"},{"key":"2022061620195957600_B22","doi-asserted-by":"crossref","unstructured":"Murthy V., Haddad L. A., Smith N., Pinney D., Tyszkowski R., Brown D., Ramesh V. Similarities and differences in the subcellular localization of hamartin and tuberin in the kidney. Am. J. Physiol. Renal Physiol., 278:\u2008F737-F746, \u20082000.","DOI":"10.1152\/ajprenal.2000.278.5.F737"},{"key":"2022061620195957600_B23","doi-asserted-by":"crossref","unstructured":"Alessi D. R., Andjelkovic M., Caudwell B., Cron P., Morrice N., Cohen P., Hemmings B. A. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J., 15:\u20086541-6551, \u20081996.","DOI":"10.1002\/j.1460-2075.1996.tb01045.x"},{"key":"2022061620195957600_B24","doi-asserted-by":"crossref","unstructured":"Casamayor A., Morrice N. A., Alessi D. R. Phosphorylation of Ser-241 is essential for the activity of 3-phosphoinositide-dependent protein kinase-1: identification of five sites of phosphorylation in vivo. Biochem. J., 342:\u2008287-292, \u20081999.","DOI":"10.1042\/bj3420287"},{"key":"2022061620195957600_B25","doi-asserted-by":"crossref","unstructured":"Cantley L. C., Neel B. G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase\/AKT pathway. Proc. Natl. Acad. Sci. USA, :\u20084240-4245, \u20081999.","DOI":"10.1073\/pnas.96.8.4240"},{"key":"2022061620195957600_B26","doi-asserted-by":"crossref","unstructured":"Liaw D., Marsh D. J., Li J., Dahia P. L., Wang S. I., Zheng Z., Bose S., Call K. M., Tsou H. C., Peacocke M., Eng C., Parsons R. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet., 16:\u200864-67, \u20081997.","DOI":"10.1038\/ng0597-64"},{"key":"2022061620195957600_B27","doi-asserted-by":"crossref","unstructured":"Tok Celebi J., Chen F. F., Zhang H., Ping X. L., Tsou H. C., Peacocke M. Identification of PTEN mutations in five families with Bannayan-Zonana syndrome. Exp. Dermatol., 8:\u2008134-139, \u20081999.","DOI":"10.1111\/j.1600-0625.1999.tb00361.x"},{"key":"2022061620195957600_B28","doi-asserted-by":"crossref","unstructured":"Li Y., Inoki K., Vacratsis P., Guan K. L. The p38 and MK2 kinase cascade phosphorylates tuberin, the tuberous sclerosis 2 gene product, and enhances its interaction with 14\u20133-3. J. Biol. Chem., 278:\u200813663-13671, \u20082003.","DOI":"10.1074\/jbc.M300862200"},{"key":"2022061620195957600_B29","doi-asserted-by":"crossref","unstructured":"Tee A. R., Anjum R., Blenis J. Inactivation of the tuberous sclerosis complex-1 and 2 gene products occurs by phosphoinositide 3 -kinase\/Akt-dependent and independent phosphorylation of tuberin. J. Biol. Chem., 278:\u200837288-37296, \u20082003.","DOI":"10.1074\/jbc.M303257200"},{"key":"2022061620195957600_B30","unstructured":"Govindarajan B., Mizesko M. C., Miller M. S., Onda H., Nunnelly M., Casper K., Brat D., Cohen C., Arbiser J. L. Tuberous sclerosis-associated neoplasms express activated p42\/44 mitogen-activated protein (MAP) kinase, and inhibition of MAP kinase signaling results in decreased in vivo tumor growth. Clin. Cancer Res., 9:\u20083469-3475, \u20082003."},{"key":"2022061620195957600_B31","doi-asserted-by":"crossref","unstructured":"Nguyen-Vu P. A., Fackler I., Rust A., DeClue J. E., Sander C. A., Volkenandt M., Flaig M., Yeung R. S., Wienecke R. Loss of tuberin, the tuberous-sclerosis-complex-2 gene product is associated with angiogenesis. J. Cutan. Pathol., 28:\u2008470-475, \u20082001.","DOI":"10.1034\/j.1600-0560.2001.028009470.x"},{"key":"2022061620195957600_B32","unstructured":"El-Hashemite N., Walker V., Zhang H., Kwiatkowski D. J. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res., 63:\u20085173-5177, \u20082003."},{"key":"2022061620195957600_B33","doi-asserted-by":"crossref","unstructured":"Brugarolas J. B., Vazquez F., Reddy A., Sellers W. R., Kaelin W. G. TSC2 regulates VEGF through mTOR-dependent and independent pathways. Cancer Cell, 4:\u2008147-158, \u20082003.","DOI":"10.1016\/S1535-6108(03)00187-9"},{"key":"2022061620195957600_B34","doi-asserted-by":"crossref","unstructured":"Takahashi K., Saishin Y., Silva R. L., Oshima Y., Oshima S., Melia M., Paszkiet B., Zerby D., Kadan M. J., Liau G., et al A. Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment. FASEB J., 17:\u2008896-898, \u20082003.","DOI":"10.1096\/fj.02-0824fje"},{"key":"2022061620195957600_B35","doi-asserted-by":"crossref","unstructured":"Barnabe-Heider F., Miller F. D. Endogenously produced neurotrophins regulate survival and differentiation of cortical progenitors via distinct signaling pathways. J. Neurosci., 23:\u20085149-5160, \u20082003.","DOI":"10.1523\/JNEUROSCI.23-12-05149.2003"},{"key":"2022061620195957600_B36","doi-asserted-by":"crossref","unstructured":"Kyin R., Hua Y., Baybis M., Scheithauer B., Kolson D., Uhlmann E., Gutmann D., Crino P. B. Differential cellular expression of neurotrophins in cortical tubers of the tuberous sclerosis complex. Am. J. Pathol., 159:\u20081541-1554, \u20082001.","DOI":"10.1016\/S0002-9440(10)62539-4"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/64\/3\/812\/2522546\/zch00304000812.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/64\/3\/812\/2522546\/zch00304000812.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T03:17:28Z","timestamp":1706584648000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/64\/3\/812\/512213\/Phosphorylation-of-Tuberin-as-a-Novel-Mechanism"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2,1]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2004,2,10]]},"published-print":{"date-parts":[[2004,2,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-03-3277","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,2,1]]}}}